Aura Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Accumulated · Total
Common Stock · Paid-In · Treasury Stock · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Shares	Amount	Deficit	Loss	Equity
Balance, December 31, 2025	63,587,777	$—	$617,433	—	$—	$(480,418)	$(102)	$136,913
Stock-based compensation expense	—	—	3,824	—	—	—	—	3,824
Employee Stock Purchase Plan issuance	24,214	—	121	—	—	—	—	121
Stock option exercises	12,733	—	56	—	—	—	—	56
Common stock warrant exercises	25,000	—	123	—	—	—	—	123
Vesting of restricted stock	500,744	—	—	—	—	—	—	—
Unrealized loss on marketable securities	—	—	—	—	—	—	(78)	(78)
Currency translation adjustment	—	—	—	—	—	—	(27)	(27)
Net loss	—	—	—	—	—	(33,685)	—	(33,685)
Balance, March 31, 2026	64,150,468	$—	$621,557	—	$—	$(514,103)	$(207)	$107,247
Stock-based compensation expense	—	—	12,368	—	—	—	—	12,368
Stock option exercises	10,720	—	80	—	—	—	—	80
Vesting of restricted stock	142,085	—	—	—	—	—	—	—
Unrealized loss on marketable securities	—	—	—	—	—	—	(290)	(290)
Issuance of common stock through follow-on offering, net of issuance costs of $618	46,099,650	1	259,383	—	—	—	—	259,384
Issuance of pre-funded warrants through follow-on offering, net of issuance costs of $51	—	—	21,381	—	—	—	—	21,381
Repurchase of common stock, including transaction costs of $48	(6,922,870)	—	—	6,922,870	(39,093)	—	—	(39,093)
Currency translation adjustment	—	—	—	—	—	—	(173)	(173)
Net loss	—	—	—	—	—	(45,637)	—	(45,637)
Balance, June 30, 2026	103,480,053	1	914,769	6,922,870	(39,093)	(559,740)	(670)	315,267
Additional · Accumulated · Total
Common Stock · Paid-In · Treasury Stock · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Shares	Amount	Deficit	Income	Equity
Balance, December 31, 2024	49,998,279	$—	$525,934	—	$—	$(374,227)	$263	$151,970
Stock-based compensation expense	—	—	3,514	—	—	—	—	3,514
Employee Stock Purchase Plan issuance	15,263	—	96	—	—	—	—	96
Vesting of restricted stock	211,770	—	—	—	—	—	—	—
Unrealized loss on marketable securities	—	—	—	—	—	—	(137)	(137)
Currency translation adjustment	—	—	—	—	—	—	(21)	(21)
Other	—	—	27	—	—	—	—	27
Net loss	—	—	—	—	—	(27,483)	—	(27,483)
Balance, March 31, 2025	50,225,312	$—	$529,571	—	$—	$(401,710)	$105	$127,966
Stock-based compensation expense	—	—	3,833	—	—	—	—	3,833
Stock option exercises	1,424	—	2	—	—	—	—	2
Vesting of restricted stock	108,749	—	—	—	—	—	—	—
Unrealized loss on marketable securities	—	—	—	—	—	—	(88)	(88)
Issuance of common stock through follow-on offering, net of issuance costs of $384	11,735,565	—	46,517	—	—	—	—	46,517
Issuance of pre-funded warrants through follow-on offering, net of issuance costs of $117	—	—	14,156	—	—	—	—	14,156
Issuance of common stock warrants through follow-on offering, net of issuance costs of $76	—	—	9,254	—	—	—	—	9,254
Currency translation adjustment	—	—	—	—	—	—	8	8
Net loss	—	—	—	—	—	(27,019)	—	(27,019)
Balance, June 30, 2025	62,071,050	—	603,333	—	—	(428,729)	25	174,629

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.